Parmax Pharma Ltd Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Cr

Standalone Quarterly Results

Jun'26

Mar'26

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Quarterly Analysis Highlights - YoY

Net Sales

YoY Growth in quarter ended Jun 2026 is 323.71% vs -75.19% in Jun 2025

Standalone Net Profit

YoY Growth in quarter ended Jun 2026 is 389.47% vs -7,700.00% in Jun 2025

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Jun 2026 is 432.00% vs -148.08% in Jun 2025

Interest

YoY Growth in quarter ended Jun 2026 is -17.86% vs 154.55% in Jun 2025

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Jun 2026 has improved from Jun 2025

Compare Quarterly Results Of Parmax Pharma With

Select Peers

Figures in Cr

Standalone Quarterly Results

Change(INR)

Change(%)

Net Sales

8.22

15.96

-7.74

-48.50%

Other Operating Income

0.00

Total Operating income

8.22

15.96

-7.74

-48.50%

Raw Material Cost

5.04

5.79

-0.75

-12.95%

Purchase of Finished goods

0.00

0.65

-0.65

-100.00%

(Increase) / Decrease In Stocks

0.69

-0.35

1.04

297.14%

Employee Cost

0.64

4.24

-3.60

-84.91%

Power Cost

0.00

Manufacturing Expenses

-0.01

0.00

-0.01

Selling and Distribution Expenses

0.00

Other Expenses

1.03

4.44

-3.41

-76.80%

Total Expenditure (Excl Depreciation)

7.39

14.77

-7.38

-49.97%

Operating Profit (PBDIT) excl Other Income

0.83

1.19

-0.36

-30.25%

Other Income

2.08

0.05

2.03

4,060.00%

Operating Profit (PBDIT)

2.91

1.24

1.67

134.68%

Interest

0.23

0.12

0.11

91.67%

Exceptional Items

0.00

Gross Profit (PBDT)

2.68

1.12

1.56

139.29%

Depreciation

0.48

0.73

-0.25

-34.25%

Profit Before Tax

2.20

0.39

1.81

464.10%

Tax

0.00

0.09

-0.09

-100.00%

Provisions and contingencies

0.00

Profit After Tax

2.20

0.30

1.90

633.33%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

2.20

0.30

1.90

633.33%

Equity Capital

3.74

1.20

2.54

211.67%

Face Value

10.00

0.00

Reserves

0.00

Earnings per share (EPS)

5.88

2.50

3.38

135.20%

Diluted Earnings per share

5.88

2.48

3.40

137.10%

Operating Profit Margin (Excl OI)

10.10%

7.46%

0.00

2.64%

Gross Profit Margin

32.60%

7.02%

0.00

25.58%

PAT Margin

26.76%

1.88%

0.00

24.88%

Public Share Holdings (%)

0.00%

0.00

0.00%

Pledged Promotor Holding (%)

0.00%

0.00

0.00%

Quarterly - Net Sales

Net Sales 8.22 Cr

in Jun 2026

Figures in Cr

QoQ Growth in quarter ended Jun 2026 is 148.34% vs -23.56% in Mar 2026

YoY Growth in quarter ended Jun 2026 is 323.71% vs -75.19% in Jun 2025

Quarterly - Standalone Net Profit

Standalone Net Profit 2.20 Cr

in Jun 2026

Figures in Cr

QoQ Growth in quarter ended Jun 2026 is 479.31% vs 20.55% in Mar 2026

YoY Growth in quarter ended Jun 2026 is 389.47% vs -7,700.00% in Jun 2025

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 0.83 Cr

in Jun 2026

Figures in Cr

QoQ Growth in quarter ended Jun 2026 is 153.55% vs -715.79% in Mar 2026

YoY Growth in quarter ended Jun 2026 is 432.00% vs -148.08% in Jun 2025

Quarterly - Interest

Interest 0.23 Cr

in Jun 2026

Figures in Cr

QoQ Growth in quarter ended Jun 2026 is -54.00% vs 78.57% in Mar 2026

YoY Growth in quarter ended Jun 2026 is -17.86% vs 154.55% in Jun 2025

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 10.10%

in Jun 2026

Figures in %

QoQ Growth in quarter ended Jun 2026 has improved from Mar 2026

YoY Growth in quarter ended Jun 2026 has improved from Jun 2025